Key result
Rosiglitazone reduced infarct size by 17% and improved cardiac function in wild-type mice (P<0.01), but these cardioprotective effects were lost in adiponectin knockout mice.
Why the study?
Does rosiglitazone improve cardioprotection against ischemic heart injury in wild-type and adiponectin knockout mice?
Does rosiglitazone improve cardioprotection against ischemic heart injury in wild-type and adiponectin knockout mice?
p-value: p=<0.01
The cardioprotective effects of the PPAR-gamma agonist rosiglitazone against ischemic injury are critically dependent on its ability to stimulate adiponectin production.
Rosiglitazone cardioprotection may require adiponectin in mice; hypothesis-generating and leaves open human translation.
No takes yet. Share an insight, caveat, or question.
Tao et al. (2009) studied Ischemic heart injury. Rosiglitazone vs. Vehicle was evaluated on Infarct size, apoptosis, oxidative stress, cardiac function, and postischemic survival rate (p=<0.01). Rosiglitazone reduced infarct size by 17% and improved cardiac function in wild-type mice (P<0.01), but these cardioprotective effects were lost in adiponectin knockout mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: